#USA #New York #GRIN Therapeutics #Radiprodil #Angelini Pharma

Strategic Collaboration Between GRIN Therapeutics and Angelini Pharma

Introduction

In a pivotal move to enhance treatments for serious neurodevelopmental disorders, GRIN Therapeutics, a trailblazer in developing precision therapeutic solutions, has announced its collaboration with Angelini Pharma. This partnership aims to develop and commercialize Radiprodil, the company’s investigational drug, outside of North America. The announcement not only signifies an important alliance in the pharmaceutical landscape but also showcases a significant financial backing stream to boost their joint mission.

Financial Overview

GRIN Therapeutics closed a $140 million Series D financing round, which includes a strategic investment from Angelini Pharma worth $65 million and an additional $75 million from Blackstone Life Sciences, a prominent investor in GRIN. This capital will significantly support ongoing operations, particularly the planned global pivotal Phase 3 trial of Radiprodil, set for commencement in Q3 2025. The collaboration agreement specifies that GRIN will receive an upfront payment of $50 million, along with the potential to earn up to $520 million based on various developmental and sales milestones.

Radiprodil’s Role

Radiprodil serves as a targeted and selective negative allosteric modulator of the GluN2B subunit of the NMDA receptor, which is critical for cognitive function and managing seizures. It is being explored for its efficacy in treating multiple rare genetic forms of epilepsy and other neurodevelopmental disorders. The drug has received multiple regulatory designations, including Breakthrough Therapy designation from the FDA, supported by promising results from clinical trials thus far.

The Impact of the Collaboration

This collaboration taps into Angelini Pharma’s extensive global market presence and expertise in dealing with complex neurological disorders.